GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Are Mesenchymal Stem Cells?

Mesenchymal stem cells (MSCs), more precisely called mesenchymal stromal cells in many studies, are a diverse group of cells isolated from tissues such as bone marrow, fat and umbilical cord. In laboratory tests, they can form bone, fat and cartilage cells. That ability does not mean an injection can rebuild those tissues in a person.16923606

The distinction between stem and stromal matters. The International Society for Cell & Gene Therapy recommends using “stromal” unless there is rigorous evidence of stem-cell properties, including self-renewal and differentiation in laboratory and living-system studies. It also recommends naming the tissue source rather than treating all MSCs as one interchangeable product.31526643

What Are Mesenchymal Stem Cells?

How Are MSCs Identified?

The widely used 2006 ISCT definition sets three minimum criteria for cultured human MSCs. These identify a laboratory cell population; they do not establish that a treatment works.16923606

Criterion What the laboratory checks
Plastic adherence The cells attach to plastic under standard culture conditions.
Surface markers The cells express CD105, CD73 and CD90, while lacking CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR.
Differentiation The cells can become bone-forming, fat and cartilage-forming cells under defined laboratory conditions.

No single marker uniquely identifies an MSC. Passing this checklist does not demonstrate clinical potency, prove stemness in a patient or replace the quality and safety tests required for a particular cell medicine.1692360631526643

Where Do MSCs Come From?

Bone marrow, adipose tissue and donated birth tissues are common sources. Tissue source, donor characteristics and laboratory expansion can change the resulting cells, even when they meet the same basic definition.29859173

Source How it is collected Important distinction
Bone marrow Marrow aspiration, commonly from the hip bone Marrow contains several cell types; an expanded MSC culture is not the same as whole marrow.
Adipose tissue Liposuction or tissue excision Expanded adipose-derived MSCs are not interchangeable with an unexpanded mixed-cell preparation.
Umbilical cord or placenta Donated tissue collected after delivery For an unrelated recipient, the cells are donor-derived. Cord tissue MSCs differ from cord-blood stem cells used in blood transplantation.

Autologous cells come from the patient; allogeneic cells come from a donor. Neither term tells you whether the proposed use has been shown to work. Using your own cells also does not remove collection, processing or injection risks.

What Do MSCs Do?

Signaling and Immune Effects

MSCs are studied for the signals they release and their interactions with immune cells. Proposed effects include changing inflammation and supporting a tissue’s repair environment. These are not the same as proving that injected cells permanently replace damaged tissue. The effects depend on the cell product and the disease being treated.29859173

Laboratory Potential Versus Human Outcomes

Making cartilage-forming cells in a dish requires controlled conditions. It does not establish that an MSC injection will regenerate a worn knee joint. Likewise, a biological mechanism or an encouraging animal result cannot substitute for a controlled human trial measuring symptoms, function and harms.

In a 2012 mouse study, intravenously infused MSCs were initially trapped in the lungs, and viable donor cells were no longer detected at 24 hours. The investigators did not find living MSCs migrating to other organs. This result challenges a simple “cells travel straight to the damaged organ” story, but it does not establish how every MSC product behaves in humans.23056000

Are MSCs the Same as Blood Stem Cells?

No. Hematopoietic stem cells produce blood cells. Blood stem cell transplantation can restore blood-cell production after intensive treatment for certain cancers and other disorders; the cells may come from peripheral blood, marrow or cord blood.Stem cell transplant

MSCs are a different cell population. Their laboratory differentiation is associated with connective tissues, not the full range of blood cells. Evidence for an established blood stem cell transplant therefore cannot be used to validate a clinic’s MSC injection.16923606

Which MSC Treatments Have Regulatory Approval?

Approval applies to a named product, a defined indication and a particular jurisdiction. Two examples are Ryoncil in the United States and Temcell in Japan, both used for acute graft-versus-host disease (GVHD). GVHD occurs when donor immune cells attack the recipient’s tissues after an allogeneic blood stem cell transplant.Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host000215658.pdf

Ryoncil in the United States

The FDA approved Ryoncil (remestemcel-L-rknd) in December 2024 for steroid-refractory acute GVHD in children aged 2 months and older. It is an allogeneic bone-marrow-derived MSC product. The approval study was multicenter and single-arm, with results based on 54 treated pediatric participants. At day 28, 16 participants (30%) had a complete response and 22 (41%) had a partial response.Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host

The recommended initial course is 2 million MSCs per kilogram per intravenous infusion, twice weekly for four weeks: eight infusions, at least three days apart. Further dosing depends on response and the prescribing information. The label says the mechanism is unclear but may involve immune modulation. A day-28 response is not a promise of cure or long-term survival; without a concurrent control group, this study cannot by itself measure the extra benefit over standard care.DrugInfo.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659

Temcell in Japan

Japan approved Temcell, another allogeneic bone-marrow-derived MSC product, in September 2015 for acute GVHD following hematopoietic stem cell transplantation. Its indication does not establish benefit for arthritis, multiple sclerosis or cosmetic use.000215658.pdf

Alofisel’s EU Withdrawal

Alofisel (darvadstrocel), an adipose-derived MSC product for complex perianal fistulas in adults with Crohn’s disease, received EU authorization in 2018. Its authorization was withdrawn on 13 December 2024 at the company’s request after confirmatory evidence failed to establish sufficient benefit. EMA reported that the 568-patient ADMIRE-CD II trial did not meet its primary endpoint of combined remission at 24 weeks. No new safety signals were identified in that trial, but the lack of confirmed benefit changed the benefit–risk assessment.AlofiselAlofisel withdrawn eu market

What Does Research Show for Arthritis and MS?

Knee Osteoarthritis

A 2025 systematic review of MSC injections for knee osteoarthritis included eight randomized trials with 467 patients, comparing injections into the joint against inert placebo. At six months, the review estimated that contextual effects accounted for approximately 63% of pain reduction and 61% of functional improvement. Evidence certainty was low; the authors described a modest incremental benefit from the cells.41041444

These percentages are estimates about average improvement, not the percentage of patients cured. They should not be interpreted as a precise causal split for an individual person. Symptom improvement also does not, by itself, demonstrate cartilage regrowth.

Progressive Multiple Sclerosis

SMART-MS, reported in 2026, was a randomized, double-blind, placebo-controlled phase I/II crossover trial involving 18 people with progressive MS in Norway. It tested a single intrathecal injection, into the fluid around the spinal cord, of autologous bone-marrow MSCs at 1 million cells per kilogram. The primary endpoint, change in combined evoked-potential latency at six months, did not differ significantly between groups.42081777

Some exploratory or secondary signals at six months, including reduced brain atrophy on MRI, were not sustained at 12 months. Fever and low back pain were common. Seven patients had spinal MRI abnormalities, and one developed chronic pain attributed to arachnoiditis. The small sample limits conclusions, and nerve-signal timing is not the same as improved walking or disability. These findings do not establish benefit from another cell type, dose or injection route.42081777

What Are the Risks?

Risks depend on the product, manufacturing process, route and patient’s condition. Ryoncil’s labeling reports infections, fever, bleeding, edema, abdominal pain and hypertension among common adverse reactions in its study population. It also warns about hypersensitivity and acute infusion reactions, infectious-agent transmission and ectopic tissue formation. These findings should not be treated as risk rates for every MSC procedure.DrugInfo.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659

  • Collection and processing. Marrow aspiration or liposuction carries procedural risks. Contamination or inadequate processing can introduce infection.
  • Injection route. A spinal injection has different risks from an infusion into a vein or an injection into a joint. SMART-MS illustrates why route-specific safety data matter.42081777
  • Unapproved products. The FDA has received reports of blindness, tumors and serious infections involving unapproved regenerative medicine products. These reports concern a broad product category, not a single standardized MSC medicine.Important patient and consumer information about regenerative medicine therapies
  • Immune reactions. Donor MSCs are not universally “immune privileged.” Antibody formation and rejection have been described; immune effects vary across settings.24561556
  • Long-term uncertainty. Short follow-up cannot establish lifetime safety. Ask about the follow-up available for the exact product, including monitoring for abnormal tissue growth and immune effects.

Why Can Two MSC Products Differ?

The name “MSC” is not a standardized dose or manufacturing specification. Tissue source, culture conditions, number of passages, fresh versus frozen storage and functional testing can affect the resulting product. A marker panel alone does not establish that two products have the same effects.29859173

Ask which cell-processing facility makes the preparation and what tests it uses for identity, viability, contamination and intended function. A facility permit or a cell-count result is not evidence that the proposed treatment improves your condition.

How Is MSC Treatment Regulated in Japan?

Japan distinguishes approval of a manufactured cell medicine from the provision of clinic-based regenerative medicine. Temcell followed the product-approval pathway involving PMDA review and Ministry of Health, Labour and Welfare approval.000215658.pdf

Clinical provision of relevant cell-based interventions is governed by the Act on the Safety of Regenerative Medicine. Its procedures include certified committee review, submission of a provision plan and reporting obligations. Cell processing is not necessarily performed on the clinic’s premises. A provision-plan number is not a marketing authorization or proof of clinical benefit.Index

How Can You Assess an MSC Offer?

A Practical Comparison

Suppose you are considering an intravenous infusion of donor cord-derived MSCs for knee pain, and the provider cites a study of a patient’s own marrow cells injected into the knee. The cell source, donor relationship and route all differ, so that study cannot directly establish the offered infusion’s effectiveness. A citation to Ryoncil’s approval would also be a mismatch: its indication is pediatric steroid-refractory acute GVHD, not knee pain.29859173Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host

Before agreeing to treatment, request written answers to these questions:

  • What is the exact product, tissue source and donor relationship?
  • Is this an approved use, a clinical trial or a privately offered intervention?
  • What dose and injection route are proposed?
  • Does the supporting study match your diagnosis, cell preparation and route?
  • Was there a control group, and did the study measure symptoms or function rather than only a laboratory or imaging marker?
  • What harms occurred, how long were patients followed, and who handles complications?
  • What are the alternatives, the total treatment costs and the cancellation terms?

A trial registration is a record of research, not proof of a positive result or permission to market a treatment. Ask for the published results as well as any registration number.Important patient and consumer information about regenerative medicine therapies

Questions about arranging a consultation in Japan?

The independently operated patient support team can help with appointment enquiries. This is not a medical consultation or a treatment recommendation. Start with a general question rather than sending sensitive medical records.

Contact patient support

Bottom Line

MSCs are cells characterized by laboratory behavior, not a universal repair treatment. Their ability to form connective-tissue cells in culture does not prove that an injection will regenerate an organ. For any proposed use, the useful questions are which cells, for which condition, delivered how, and supported by what human evidence.

Sources

  1. Dominici M et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy, 2006. ISCT position statement.
  2. Viswanathan S et al. Mesenchymal stem versus stromal cells. Cytotherapy, 2019. ISCT nomenclature statement.
  3. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell, 2018. Review of MSC translation and product variability.
  4. Eggenhofer E et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Frontiers in Immunology, 2012. Mouse tracking study.
  5. National Cancer Institute. Stem Cell Transplants in Cancer Treatment.
  6. FDA. Ryoncil approval announcement, 18 December 2024.
  7. PMDA. Temcell review report, 2015.
  8. DailyMed, U.S. National Library of Medicine. Ryoncil prescribing information, label updated September 2025.
  9. EMA. Alofisel authorization and withdrawal record.
  10. EMA. Alofisel withdrawn from the EU market, 13 December 2024.
  11. Contextual effects of mesenchymal stem cell injections for knee osteoarthritis. Frontiers in Medicine, 2025. Systematic review and meta-analysis.
  12. Intrathecal Mesenchymal Stem Cells in Progressive Multiple Sclerosis: SMART-MS. Neurology, 2026. Randomized phase I/II crossover trial.
  13. FDA. Important Patient and Consumer Information About Regenerative Medicine Therapies.
  14. Ankrum JA et al. Mesenchymal stem cells: immune evasive, not immune privileged. Nature Biotechnology, 2014. Review of immune recognition.
  15. MHLW. Regenerative and cell medicine and gene therapy (Japanese).

General information only, not medical advice or a recommendation for a particular treatment. Discuss personal decisions with a qualified clinician. Updated October 2026.